Table 1. Baseline patient characteristics of 1,542 patients diagnosed with high-risk NMIBC stratified by low versus-high intesity cystoscopic surveillance.
| Total / All patients (n = 1542) | High intensity surveillance (n = 1022) | Low intensity surveillance (n = 520) | P-value * | |
|---|---|---|---|---|
| Age (median, IQR) | 77 (66–95) | 76 (66–95) | 77 (66–94) | 0.04 |
| Age ≥80 (N, %) | 555 (36) | 343 (33.6) | 212 (40.8) | <0.01 |
| Male Sex (N, %)** | >1531 (>99.2) | >1011 (>98.9) | >509 (>97.8) | 0.33 |
| Race (N, %) | ||||
| White** | >1273 (>82.5) | >856 (>83.7) | 414 (79.6) | 0.04 |
| Black | 113 (7.3) | 60 (5.9) | 53 (10.2) | |
| Asian** | 14 (0.9) | 11 (1.1) | <11 (<2.2) | |
| Hispanic** | 23 (1.5) | 16 (1.6) | <11 (<2.2) | |
| Native American** | <11 (<0.8) | <11 (<1.1) | <11 (<2.2) | |
| Unknown | 108 (7) | 68 (6.7) | 40 (7.7) | |
| Comorbidity (N, %) | ||||
| 0 | 226 (14.7) | 142 (13.9) | 84 (16.2) | 0.39 |
| 1 | 403 (26.1) | 273 (26.7) | 130 (25) | |
| 2 | 404 (26.2) | 277 (27.1) | 127 (24.4) | |
| ≥3 | 509 (33) | 330 (32.3) | 179 (34.4) | |
| Nosos-p score *** (median, IQR) | 1.6 (0.4–7.5) | 1.7 (0.5–7.5) | 1.5 (0.4–7.3) | 0.01 |
| Year of diagnosis (N, %) | ||||
| 2005 | 33 (2.1) | 20 (2) | 13 (2.5) | 0.33 |
| 2006 | 182 (11.8) | 121 (11.8) | 61 (11.7) | |
| 2007 | 222 (14.4) | 140 (13.7) | 82 (15.8) | |
| 2008 | 267 (17.3) | 164 (16) | 103 (19.8) | |
| 2009 | 269 (17.4) | 184 (18) | 85 (16.3) | |
| 2010 | 312 (20.2) | 215 (21) | 97 (18.7) | |
| 2011 | 257 (16.7) | 178 (17.4) | 79 (15.2) | |
| Proportion living in ZIP code with ≥25% college graduates (N, %) | 645 (41.8) | 436 (42.7) | 209 (40.2) | 0.35 |
| Living in urban vs. rural area (N, %) | ||||
| Urban | 929 (60.2) | 608 (59.5) | 321 (61.7) | 0.40 |
| Rural | 613 (39.8) | 414 (40.5) | 199 (38.3) | |
| Stage | ||||
| Ta (high grade or associated with carcinoma in situ) | 599 (38.8) | 404 (39.5) | 195 (37.5) | 0.69 |
| T1 | 872 (56.5) | 570 (55.8) | 302 (58.1) | |
| Carcinoma in situ only | 71 (4.6) | 48 (4.7) | 23 (4.4) | |
| Carcinoma in situ | 330 (21.4) | 227 (22.2) | 103 (19.8) | 0.28 |
| Bladder Cancer Grade | ||||
| Low**** | 196 (12.7) | 123 (12) | 73 (14) | 0.26 |
| High | 1346 (87.3) | 899 (88) | 447 (86) | |
| Intravesical Therapy (N,%)***** | 859 (56) | 597 (58) | 262 (50) | <0.01 |
* From Chi-square test for categorical variable and Wilcoxon test for continuous variables whose median and IQR were presented. Missing observations were excluded for analysis.
** Exact numbers not shown to protect confidentiality.
*** The Nosos-p score is a risk-adjustment score based on diagnosis codes, biographic information (including gender, date of birth, insurance coverage, race, marital status, VA priority (priority 1–9), and inclusion in a VA registry), drug prescription data and utilization costs. The “-p” indicates it is a prospective score, using data from one fiscal year to predict future health care utilization in the next fiscal year.
**** Low-grade tumors were only included if they were T1 or associated with carcinoma in situ.
***** Not included in initial propensity score adjustment. However, all Fine-Gray models were adjusted for receipt on intravesical chemotherapy.